دورية أكاديمية
Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production.
| العنوان: | Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production. |
|---|---|
| المؤلفون: | Franssen R; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands., Sankatsing RR, Hassink E, Hutten B, Ackermans MT, Brinkman K, Oesterholt R, Arenas-Pinto A, Storfer SP, Kastelein JJ, Sauerwein HP, Reiss P, Stroes ES |
| المصدر: | Arteriosclerosis, thrombosis, and vascular biology [Arterioscler Thromb Vasc Biol] 2009 Sep; Vol. 29 (9), pp. 1336-41. Date of Electronic Publication: 2009 Aug 10. |
| نوع المنشور: | Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9505803 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1524-4636 (Electronic) Linking ISSN: 10795642 NLM ISO Abbreviation: Arterioscler Thromb Vasc Biol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 1998- : Baltimore, Md. : Lippincott Williams & Wilkins Original Publication: Dallas, TX : American Heart Association, c1995- |
| مواضيع طبية MeSH: | Anti-HIV Agents/*therapeutic use , Apolipoprotein A-I/*blood , Cholesterol, HDL/*blood , HIV Infections/*drug therapy , HIV-1/*isolation & purification , Nevirapine/*therapeutic use , Reverse Transcriptase Inhibitors/*therapeutic use, Adult ; Antiretroviral Therapy, Highly Active ; Dideoxynucleosides/therapeutic use ; HIV Infections/blood ; HIV Infections/virology ; HIV-1/genetics ; Humans ; Kinetics ; London ; Magnetic Resonance Spectroscopy ; Male ; Middle Aged ; Netherlands ; RNA, Viral/blood ; Treatment Outcome ; Up-Regulation ; Viral Load |
| مستخلص: | Objective: The purpose of this study was to investigate the mechanism by which the nonnucleoside reverse transcriptase inhibitor (NNRTI) nevirapine (NVP) increases high-density lipoprotein cholesterol (HDLc) in treatment-experienced human immunodeficiency virus-1 (HIV-1)-infected patients. Methods and Results: Twelve HIV-1 infected patients, with stably suppressed HIV-1 viral load using AZT/3TC/abacavir for > or =6 months, added NVP to their current antiretroviral regimen. Patients received a primed bolus infusion of the stable isotope L-[1-(13)C]-valine for 12 hours before, as well as 6 and 24 weeks after, the addition of NVP to study apolipoprotein A-I (apoA-I) kinetics. Absolute production rate (APR) and fractional catabolic rate (FCR) of apoA-I were calculated using SAAM-II modeling. Major HDLc-modulating enzymes were assessed. Plasma apoA-I and HDLc levels increased significantly after 24 weeks of treatment by, respectively, 13+/-4% (P=0.01) and 16+/-6% (P=0.015). Concomitantly, apoA-I production rate at 24 weeks increased by 17+/-7% (P=0.04). ApoA-I catabolism did not change. A modest increase of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein activity was observed. Conclusions: NVP increases apoA-I production, which contributes to the HDLc increase after introduction of NVP-containing regimens. In view of the potent antiatherogenic effects of apoA-I, the observed increase may contribute to the favorable cardiovascular profile of NVP. |
| المشرفين على المادة: | 0 (APOA1 protein, human) 0 (Anti-HIV Agents) 0 (Apolipoprotein A-I) 0 (Cholesterol, HDL) 0 (Dideoxynucleosides) 0 (RNA, Viral) 0 (Reverse Transcriptase Inhibitors) 99DK7FVK1H (Nevirapine) WR2TIP26VS (abacavir) |
| تواريخ الأحداث: | Date Created: 20090812 Date Completed: 20090908 Latest Revision: 20220321 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1161/ATVBAHA.109.192088 |
| PMID: | 19667106 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1524-4636 |
|---|---|
| DOI: | 10.1161/ATVBAHA.109.192088 |